School of Medicine Faculty Publications

School of Medicine

6-30-2022

Assessing COVID-19 Booster Hesitancy and Its Correlates: An
Early Evidence from India
Geetanjali C. Achrekar
GVMs College of Commerce and Economics

Kavita Batra
University of Nevada, Las Vegas, kavita.batra@unlv.edu

Yashashri Urankar
Community Health Centers of South-Central Texas

Ravi Batra
Coforge

Naved Iqbal
Jamia Millia Islamia
Follow this and additional works at: https://digitalscholarship.unlv.edu/som_fac_articles
Part of the Community Health and Preventive Medicine Commons, Epidemiology Commons, Health
See next page for additional authors
Services Research Commons, and the International Public Health Commons

Repository Citation
Achrekar, G. C., Batra, K., Urankar, Y., Batra, R., Iqbal, N., Choudhury, S. A., Hooda, D., Khan, R., Arora, S.,
Singh, A., Chirico, F., Sharma, M. (2022). Assessing COVID-19 Booster Hesitancy and Its Correlates: An
Early Evidence from India. Vaccines, 10(7), 1-13.
http://dx.doi.org/10.3390/vaccines10071048

This Article is protected by copyright and/or related rights. It has been brought to you by Digital Scholarship@UNLV
with permission from the rights-holder(s). You are free to use this Article in any way that is permitted by the
copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from
the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/
or on the work itself.
This Article has been accepted for inclusion in School of Medicine Faculty Publications by an authorized
administrator of Digital Scholarship@UNLV. For more information, please contact digitalscholarship@unlv.edu.

Authors
Geetanjali C. Achrekar, Kavita Batra, Yashashri Urankar, Ravi Batra, Naved Iqbal, Sabiha A. Choudhury,
Deepti Hooda, Roohi Khan, Suraj Arora, Aditi Singh, Francesco Chirico, and Manoj Sharma

This article is available at Digital Scholarship@UNLV: https://digitalscholarship.unlv.edu/som_fac_articles/748

Article

Assessing COVID-19 Booster Hesitancy and Its Correlates:
An Early Evidence from India
Geetanjali C. Achrekar 1,† , Kavita Batra 2,3, *,† , Yashashri Urankar 4 , Ravi Batra 5 , Naved Iqbal 6 ,
Sabiha A. Choudhury 7 , Deepti Hooda 8 , Roohi Khan 9 , Suraj Arora 10 , Aditi Singh 11 , Francesco Chirico 12
and Manoj Sharma 13
1

2

3
4
5
6
7
8

9

10

11

12

Citation: Achrekar, G.C.; Batra, K.;

13

Urankar, Y.; Batra, R.; Iqbal, N.;
Choudhury, S.A.; Hooda, D.;
Khan, R.; Arora, S.; Singh, A.; et al.

*
†

Department of Economics, GVMs College of Commerce and Economics, Ponda Goa 403401, India;
geetanjali@gvmcommercecollege.ac.in
Department of Medical Education, Kirk Kerkorian School of Medicine, University of Nevada,
Las Vegas, NV 89102, USA
Office of Research, Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas, NV 89102, USA
Community Health Centers of South-Central Texas, Gonzales, TX 78629, USA; urankary@chcsct.com
Department of Information Technology, Coforge Ltd., Atlanta, GA 30338, USA; ravi.batra123@gmail.com
Department of Psychology, Jamia Millia Islamia, New Delhi 110025, India; niqbal@jmi.ac.in
Department of Psychology, Mizoram University, Tanhril, Aizaw l796004, India; sabihachoudhury9@gmail.com
Department of Psychology, Maharshi Dayanand University, Rohtak 124001, Haryana, India;
deepti.hooda@mdurohtak.ac.in
Academics Department, London School of Commerce, Chaucer House, White Hart Yard,
London SE1 1NX, UK; roohi5060@gmail.com
Department of Restorative Dental Sciences, College of Dentistry, King Khalid University,
Abha 61321, Saudi Arabia; surajarorasgrd@yahoo.co.in
Department of Internal Medicine, Kirk Kerkorian, University of Nevada, Las Vegas, NV 89102, USA;
aditi.singh@unlv.edu
Post-graduate School of Occupational Health, Università Cattolica del Sacro Cuore, 00168 Rome, Italy;
medlavchirico@gmail.com
Department of Social and Behavioral Health, School of Public Health, University of Nevada,
Las Vegas, NV 89119, USA; manoj.sharma@unlv.edu
Correspondence: kavita.batra@unlv.edu
These authors contributed equally to this work.

Assessing COVID-19 Booster
Hesitancy and Its Correlates: An
Early Evidence from India. Vaccines
2022, 10, 1048. https://doi.org/
10.3390/vaccines10071048
Academic Editor: Juan C. De la Torre
Received: 25 May 2022
Accepted: 28 June 2022
Published: 30 June 2022
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affiliations.

Copyright: © 2022 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article

Abstract: The emergence of SARS-CoV-2 mutants, waning immunity, and breakthrough infections
prompted the use of booster doses of the COVID-19 vaccine to fight against the pandemic. India
started booster doses in January 2022 and it is critical to determine the intention of booster dose
uptake and its correlates. Therefore, the current cross-sectional study aimed to investigate booster
dose acceptability and associated predictors among the Indian population. A convenience sampling
technique was utilized to recruit a sample of 687 Indian residents. A 55-item psychometric validated
survey tool was used to assess booster dose acceptability, vaccine literacy and vaccine confidence.
Univariate, bivariate, and multivariate statistical methods were used to analyze the data. Over 50% of
participants reported their willingness to take the booster dose. Among the group not willing to take
the booster dose (n = 303, 44.1%), a significantly larger proportion of respondents were unvaccinated
with the primary series (12.2% vs. 5.2%, p < 0.001), had an annual income below 2.96 lacs/annum
(52.8% vs. 33.1, p < 0.001), were residents of rural areas (38.0% vs. 23.2%, p < 0.001), were not living
with vulnerable individuals (78.5% vs. 65.2%, p < 0.001) and did not have family/friends who had
tested positive for COVID-19 (54.6% vs. 35.1%, p = 0.001). Demographic, vaccine variables and
multi-theory model subscales to predict the initiation of booster dose among hesitant participants
were statistically significant, R2 = 0.561, F (26, 244) = 11.978, p < 0.001; adjusted R2 = 0.514. Findings
of this study highlight the need to develop evidence-based interventions to promote vaccine uptake,
particularly among hard-to-reach communities living in developing countries.

distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/

Keywords: COVID-19; vaccine hesitancy; vaccine literacy; functional literacy; communicative literacy;
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1. Introduction
Most countries around the globe have considered the administration of additional
booster doses of the COVID-19 vaccine given the emergence of new variants of SARS-CoV-2,
concerns about waning immunity, and the incidence of breakthrough infections [1–8]. The
side effects of the booster dose include systemic as well as local symptoms, including sore
arm, headache, chills, tiredness, and nausea etc. [3,4]. These side effects are mostly mild
and occur as a part of the immune response following the booster dose administration [3,4].
Reportedly, the effectiveness of the booster dose during the Omicron phase was 86% [9].
It was also found that the booster dose is 45% effective in preventing severe illness and
hospitalizations following the Delta and Omicron infections [9]. Despite the scientifically
proven and clinically tested vaccines across the world, vaccine hesitancy remains a big
challenge in implementing vaccination drives by the government. The rates of vaccine
hesitancy varied among countries, for instance, according to a recent United States (U.S.)
based study, 42 percent of the Americans were not confident to take the booster dose of the
COVID-19 vaccine [10]. The factors associated with booster dose hesitancy included but
were not limited to lack of trust and demographic characteristics. Demographic factors,
such as education status, marital status, regional differences, and political affiliation were
among the main contributing factors of the booster dose hesitancy among the general
population living in the U.S. [10]. A study related to vaccine acceptance among American
healthcare workers (HCWs) found that only 7.9% of respondents were hesitant to take
the primary series of the COVID-19 vaccine [11,12]. Individuals aged between 18 to
40 years, those with the lower educational attainment, and those lacking trust had higher
vaccine hesitancy. Additionally, over 65 percent of the respondents had concerns about the
vaccination’s effectiveness against new strains and the need to take booster doses [11,12].
A cross-sectional study among a Jordanian sample was undertaken to investigate
how individuals having two doses of the primary series vaccination feel about being
administered a booster dose and the factors associated with their decision [12]. Nearly
45 percent of the respondents were willing to take the booster dose and among the most
frequently cited reasons by the participants were the presumption of low efficacy of the
booster dose followed by the concerns surrounding short time interspersed between the
administration of the primary series and booster dose [12]. Moreover, some participants,
who acquired natural immunity subsequent to the prior COVID-19 infection did not feel
the need to take a booster dose [12]. A cross-sectional study performed in Naples (Italy)
investigated the mental readiness of a random sample of individuals, who had completed
primary vaccination regime at immunisation sites to receive the booster of the COVID-19
vaccine. The booster dose acceptability was 85.7 percent in this Naples based sample [12].
Also, older adults who had a better health state following the primary vaccine series, those
living with friends or someone among their family testing positive for COVID-19 and
who had received the disease related information from official public institutions were
willing to obtain the booster dose [12]. In a study performed among 31 Chinese provinces,
a majority (93.7%) of the participants exhibited high acceptance in receiving the third
dose of the vaccine. Individuals with lower levels of income, education, awareness and
knowledge about COVID-19 were less likely to accept/take a third dose of COVID-19 [13].
This underscores the need to develop vaccine/health literacy campaigns and community
outreach programs, especially within developing countries [14].
Scientists, researchers and policy planners view a booster dose as an effective way to
fight the COVID-19 virus; however, public acceptance of a booster dose is relatively low due
to a lack of trust and low vaccine confidence among people [15–17]. Vaccine misinformation
prevailing on social media is an important factor contributing to vaccine hesitancy, which
might have impacted the vaccine coverage rates and COVID response efforts at a global
level [16,17]. This points to the importance of measuring vaccine initiation behaviours
through tools grounded in the robust theoretical models, for instance, researchers in the
U.S. used fourth generation theoretical frameworks (e.g., multi-theory model, MTM) to
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assess hesitancy towards primary series and booster doses among different demographic
groups [18–20].
In India, the booster dose administration started in January 2022 [21] and there is a
need to examine the booster dose acceptance levels and factors associated with hesitancy.
Therefore, the objectives of the current study were twofold: first, to investigate the rate
of booster dose acceptability and its correlates among the Indian population; second,
to analyse the association between vaccine confidence, vaccine literacy and intention of
initiating COVID-19 booster dose uptake based on the robust behavioural theory model.
2. Methods
2.1. Study Design, Participants, and Data Collection
This descriptive cross-sectional study utilized an online survey to recruit a sample of
Indian nationals aged 18 years or above. Individuals who could understand the English
language and were capable of providing informed consent were included. A convenience
non-probability sampling was used to collect data during 13 December 2021–10 February
2022. The Qualtrics platform was used to deploy the survey and the survey link was shared
with a wide variety of communities, social networks of the study investigators, social
media, and other networking platforms, including WhatsApp, Facebook etc.
2.2. Ethical Considerations
This study was approved by the Institutional Human Ethics Committee of the Goa
University (GU-DRDRM/IHEC-Cert/2021/03 dated 27 September 2021). Respondents’
consent was implied at the beginning of the study and potential respondents were informed
that their participation in the study was voluntary and anonymous. Participants were
given detailed information about the objectives, benefits and harms associated with this
study, so they could make informed decisions about their participation. To abide by the
ethical guidelines, no personal identifier information was collected to ensure anonymity.
2.3. Survey Instrument
A 55-item questionnaire consisting of psychometric valid tools was used in this study.
The survey included 20 demographic and vaccine status related, 8 items to measure the
Vaccine Confidence Index (VCI), 14 items to assess functional, communicative, and critical
vaccine literacy [22,23], 13 items related to initiation of booster vaccination behavior based
on the MTM [18–20]. The MTM tool has been used in a variety of other protective behaviors,
such as mask wearing and hand-washing related to the COVID-19 [24,25]. The MTM tool
includes subscales of “perceived advantages,” “perceived disadvantages,” “behavioral
confidence,” and “changes in the physical environment.” [26]. All subscales were measured through 3 items each (12 items in total) [18–20]. One last item measured initiation,
which was used as one of the dependent variables in this study. A 5-point Likert scale of
frequency (ranging from “never” to “very often”) was used for the “perceived advantages”
and “perceived disadvantages.” The summative scores of “perceived advantages” and
“perceived disadvantages” were subtracted to calculate a derived subscale called “participatory dialogue.” The “Behavioral confidence” and “changes in physical environment” were
measured on the 5-point Likert scale (“Not at all sure” to “Completely sure”) [18–20,26,27].
2.4. Sample Size Determination
Based on a 99% confidence level, a conservative 5% margin of error, and an estimated
total adult population of 1 billion in India, 683 adults were required to make adequate
inferences to the total population of adults in India. According to a previous study conducted in an Indian context [28], nearly 37% of the population was hesitant towards the
COVID-19 vaccine, which we used as a proportion in a sample size calculation formula of
n = (z) 2 p (1 − p)/d2 (d = margin of error; z = 1.96; and p = 0.37). The estimated sample
size was 683 (621 + 10% non-response = 683) after accounting for 10% non-response.
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2.5. Data Analysis
Data were cleaned and re-coded for the analysis. New variables to represent summative scores of vaccine confidence, vaccine literacy, and initiation were created. Data
were assessed for distribution and outliers. Normally distributed continuous variables
were represented as mean and standard deviation, whereas categorical variables were
presented as counts and proportions. Given the independence of observations, chi-square
and independent-samples-t-tests were used to compare categorical and continuous outcomes respectively among groups willing to take and not willing to take booster doses.
A Pearson’s correlation analysis was conducted between main continuous variables, including age, vaccine literacy, vaccine confidence, and MTM constructs of initiation. A
hierarchical linear regression was performed to investigate the predictive effect of vaccine
literacy, confidence and MTM constructs on initiating the booster dose vaccination behavior
after controlling the model for age, gender, marital status, education, income, region, if
living with vulnerable individuals, and history of family/friends being COVID-19 positive.
The polytomous variables were dummy coded before entering in the regression equation.
Statistical significance for all tests and analyses was assumed a priori at p < 0.05. The
Statistical Package for Social Sciences for Windows, version 27.0 (SPSS, Chicago, IL, USA)
was utilized to analyze the data.
3. Results
A total of 687 respondents provided consent and completed the survey. Over 90% of
our sample reported being fully vaccinated and over 50% of the respondents indicated
their willingness to take the booster dose (Table 1). Over 60% of the sample were females
and never married. Participants were predominately from the north, north–west and
Union territories of India. Approximately 50% of the sample reported having a bachelor’s
degree and approximately 40% of the sample had an annual income below 2.96 lacs/annum
(Table 1). Five of every ten participants reported having family/friends who had tested
positive for COVID-19 and 1/4 of the participants had vulnerable individuals at home
(Table 1). About 30% of the respondents were living in rural areas. Among the group
not willing to take the booster dose (n = 303, 44.1%), a significantly larger proportion of
respondents were unvaccinated with the primary series (12.2% vs. 5.2%, p < 0.001), had
an annual income below 2.96 lacs/annum (52.8% vs. 33.1%, p < 0.001), were residents of
rural areas (38.0% vs. 23.2%, p < 0.001), were not living with vulnerable individuals (78.5%
vs. 65.2%, p < 0.001) and did not have family/friends who had tested positive for COVID19 (54.6% vs. 35.1%, p = 0.001, Table 2). The mean scores of functional, communicative,
critical, total vaccine literacies, and vaccine confidence were significantly higher among
non-hesitant group as opposed to their hesitant counterparts (Table 3). Likewise, the mean
score of “perceived advantages” of the booster dose vaccination was higher among the
group willing to take it as compared to the group who was not willing to take the booster
dose (8.56 ± 2.39 vs. 6.48 ± 2.46, p < 0.001). On the contrary, the booster hesitant group had
higher mean scores of “perceived disadvantages” as compared to the non-hesitant ones
(5.85 ± 2.34 vs. 4.75 ± 2.18, p < 0.001, Table 3). The mean scores of “behavioral confidence,”
and “changes in the physical environment,” were also higher among the booster nonhesitant group as expected (Table 3). A significantly larger proportion of the non-hesitant
group agreed that the booster dose is effective and protective against COVID-19 infections
(Figure 1). On the other hand, booster hesitant respondents were opposed to the booster
dose and think it may have serious side effects (Figure 1).
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Table 1. Demographic characteristics of the respondents (n = 687).
Variable Name
Vaccinated status (Primary Series)

Will take COVID-19 booster dose
Age (Mean ± SD)
Gender

Marital status

Education

Income

Living with vulnerable individuals

Family/friends tested COVID-19 positive

Region

Urbanity

Categories

n (%)

95% CI (LCL, UCL)

Yes

630 (91.7)

89.4, 93.6

No

57 (8.3)

6.3, 10.6

Yes

384 (55.9)

52.1, 59.6

No/Not sure

303 (44.1)

40.4, 47.9

-

25.41 ± 9.1

24.7, 26.1

Male

224 (32.6)

29.1, 36.3

Female

462 (67.2)

63.6, 70.7

Married

116 (16.9)

14.2, 19.9

Single, never married

433 (63.0)

59.3, 66.6

Others

6 (0.8)

0.3, 1.9

Bachelor’s degree

341 (49.6)

45.8, 53.4

Master’s degree

197 (28.7)

25.3, 32.2

Professional or trade school

28 (4.1)

2.7, 5.8

Some high school or diploma

121 (17.6)

14.8, 20.6

Below 2.96 lacs/annum

287 (41.8)

38.1, 45.5

2.96 lacs–6.29 lacs/annum

197 (28.7)

25.3, 32.2

6.29 lacs–29.6 lacs/annum

176 (25.6)

22.3, 29.1

Above 29.6 lacs/annum

27 (3.9)

2.6, 5.7

Yes

189 (27.5)

24.2, 31.0

No

460 (67.0)

63.3, 70.5

Yes

376 (54.7)

50.9, 58.5

No

292 (42.5)

38.7, 46.3

North

260 (37.8)

34.2, 41.5

Northeast

25 (3.6)

2.4, 5.3

South

23 (3.3)

2.1, 4.9

West

235 (34.2)

30.6, 37.8

Central

6 (0.9)

0.3, 1.9

East

27 (3.9)

2.6, 5.7

Union Territories

111 (16.2)

13.5, 19.1

Rural

204 (29.7)

26.3, 33.2

Suburban

78 (11.4)

9.1, 13.9

Urban

405 (59.0)

55.2, 62.6

Note: Some percentages may not add up to 100% as a few respondents preferred not to answer; SD = Standard
deviation; CI = Confidence Interval; LCL = Lower Confidence Level; UCL = Upper Confidence Level.
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Table 2. Bivariate comparison of Booster Dose acceptability by sample characteristics (n = 687).
Variable Name

Categories

Willing to Take BOOSTER
Yes
(n = 384, 55.9%)

No
(n = 303, 44.1%)

p Value

Statistics

ES

<0.001

10.916

0.126

Vaccinated status
(Primary Series)

Yes

364 (94.8)

266 (87.8)

No

20 (5.2)

37 (12.2)

Age

-

26.45 ± 9.99

24.00 ± 7.77

<0.001

3.494

0.261

Male

136 (35.5)

88 (29.0)

0.073

3.216

0.068

Female

247 (64.5)

215 (71.0)
0.009

9.465

0.117

0.022

9.657

0.119

<0.001

33.705

0.221

<0.001

13.591

0.145

<0.001

25.341

0.195

0.2

9.083

0.12

<0.001

19.049

0.167

Gender

Married

76 (19.8)

40 (13.2)

Single, never married

244 (63.5)

189 (62.4)

Others

64 (16.7)

74 (24.4)

Bachelor’s degree

173 (45.1)

168 (55.4)

Master’s degree

126 (32.8)

71 (23.4)

Professional or trade school

14 (3.6)

14 (4.6)

Some high school or diploma

71(18.5)

50 (16.5)

Below 2.96 lacs/annum

127 (33.1)

160 (52.8)

2.96 lacs–6.29 lacs/annum

114 (29.7)

83 (27.4)

6.29 lacs–29.6 lacs/annum

125 (32.6)

51 (16.8)

Above 29.6 lacs/annum

18 (4.7)

9 (3.0)

Living with
vulnerable individuals

Yes

130 (34.8)

59 (21.5)

No

244 (65.2)

216 (78.5)

Family/friends tested
COVID-19 positive

Yes

242 (64.9)

134 (45.4)

No

131 (35.1)

161 (54.6)

North

151 (39.3)

109 (36.0)

Northeast

16 (4.2)

9 (3.0)

Marital status

Education

Income

Region

Urbanity

South

14 (3.6)

9 (3.0)

West

117 (30.5)

118 (38.9)

Central

5 (1.3)

1 (0.3)

East

19 (4.9)

8 (2.6)

Union Territories

62 (16.1)

49 (16.2)

Rural

89 (23.2)

115 (38.0)

Suburban

43 (11.2)

35 (11.6)

Urban

252 (65.6)

153 (50.5)

ES: Effect size; p values less than 0.05 are considered statistically significant and are bolded in the table.

The Pearson correlation analysis indicated that “perceived advantages” are indirectly
correlated with “perceived disadvantages” (r = −0.263, p < 0.001) and directly correlated
with “behavioral confidence” (r = 0.547, p < 0.001), “changes in physical environment”
(r = 0.506, p < 0.001), age (r = 0.123, p < 0.001), communicative vaccine literacy (r = 0.284,
p < 0.001), critical literacy (r = 0.367, p < 0.001), and vaccine confidence (r = 0.462, p < 0.001).
The “behavioral confidence” was strongly and directly correlated with the “changes in
physical environment” (r = 0.792, p < 0.001), and moderately directly correlated with vaccine
confidence (r = 0.447, p < 0.001). The “perceived disadvantages” were indirectly correlated
with the vaccine confidence (r = −0.262, p < 0.01) (Table 4). As indicated in Table 5, the
full model of demographic, vaccine variables and MTM subscales to predict initiation
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Behavior Confidence
7.61 ± 2.87
3.85 ± 2.63
<0.001
17.683
1.35
increase in R2 of 0.153, F (1, 246) = 56.989, p < 0.001. The addition of “behavioral confidence”
Changes in the Physical Environment
7.91 ± 2.89of booster
4.74 ±dose
2.73 acceptability
<0.001 (Model 4) 14.571
1.12
to the prediction
also led to a statistically
Note:
All measures
are represented
as Mean
± standard
deviationpunless
stated otherwise.
significant
increase
in R2 of 0.130,
F (1,
245) = 60.247,
< 0.001.

Figure 1. Item-wise comparison of vaccine confidence index among groups willing to take (yes)
Figure 1. Item-wise comparison of vaccine confidence index among groups willing to take (yes)
booster dose vs. those not willing to take (no) booster dose. Note: All differences were statistically
booster dose vs. those not willing to take (no) booster dose. Note: All differences were statistically
significant at p < 0.05.
significant at p < 0.05.
Table 1. Demographic characteristics of the respondents (n= 687).

Variable Name
Vaccinated status (Primary Series)
Will take COVID-19 booster dose

Categories
Yes
No
Yes
No/Not sure

n (%)
630 (91.7)
57 (8.3)
384 (55.9)
303 (44.1)

95% CI (LCL, UCL)
89.4, 93.6
6.3, 10.6
52.1, 59.6
40.4, 47.9
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Table 4. Pearson correlations for study variables in the sample population (n = 687).
Variables

1

2

3

4

5

6

7

8

9

1. Advantages

1

−0.263 **

0.547 **

0.506 **

0.097 *

0.284 **

0.367 **

0.462 **

0.123 **

2. Disadvantages

0.263 **

1

−0.335 **

−0.288 **

−0.168 **

0.029

−0.053

−0.262 **

0.001

3. Behavioral Confidence

0.547 **

−0.335 **

1

0.792 **

0.178 **

0.240 **

0.313 **

0.447 **

0.140 **

4. Physical Environment

0.506 **

−0.288 **

0.792 **

1

0.235 **

0.270 **

0.344 **

0.454 **

0.144 **
0.069

5. Functional Literacy

0.097 *

−0.168 **

0.178 **

0.235 **

1

0.090 *

0.050

0.213 **

6.Iterative/Communicative Literacy

0.284 **

0.029

0.240 **

0.270 **

0.090 *

1

0.622 **

0.351 **

0.057

7. Critical Literacy

0.367 **

−0.053

0.313 **

0.344 **

0.050

0.622 **

1

0.292 **

0.073

8. Vaccine Confidence

0.462 **

−0.262 **

0.447 **

0.454 **

0.213 **

0.351 **

0.292 **

1

0.134 **

9. Age

0.123 **

0.001

0.140 **

0.144 **

0.069

0.057

0.073

0.134 **

1

** p < 0.01; * p < 0.05

Table 5. Hierarchical Multiple Regression (HRM) predicting intention of COVID-19 booster dose
initiation among hesitant respondents (n = 303).
Variables

Model 1

Model 2

Model 3

Model 4

Model 5

B

β

B

β

B

β

B

β

B

Constant

1.240 *

-

−0.263

-

0.249

-

0.444

-

0.708

-

Age

0.022

0.153

0.018

0.128

0.014

0.099

0.009

0.063

0.002

0.014

Gender (Ref: Female)

−0.001

0.001

0.143

0.057

0.209

0.083

0.124

0.049

0.013

0.005

β

Education (Ref: Some high school or diploma)
Bachelor’s degree

−0.081

−0.035

−0.182

−0.080

−0.143

−0.063

−0.127

−0.056

0.016

0.007

Master’s degree

−0.052

−0.020

−0.005

−0.002

0.143

0.054

0.071

0.027

0.174

0.066

Professional or trade school

−0.839 *

−0.158

−0.773 *

−0.145

−0.540

−0.102

−0.368

−0.069

−0.053

−0.010

2.96 lacs–6.29 lacs/annum

0.010

0.004

−0.079

−0.031

−0.152

−0.060

−0.047

−0.018

−0.061

−0.024

6.29 lacs–29.6 lacs/annum

0.069

0.024

−0.054

−0.019

−0.120

−0.041

−0.007

−0.002

−0.009

−0.003

Above 29.6 lacs/annum

−0.257

−0.036

−0.084

−0.012

−0.035

−0.005

−0.100

−0.014

−0.348

−0.049

Income (Ref: <2.96 Lacs/annum)

Marital status (Ref: Married)
Single

0.364

0.154

0.241

0.102

0.032

0.013

0.007

0.003

0.054

0.023

Others

0.334

0.124

0.199

0.074

0.042

0.016

0.111

0.041

0.170

0.063

Urbanity (Ref: Rural)
Suburban

−0.542 *

−0.150

−0.544 *

−0.150

−0.140

−0.039

−0.161

−0.044

−0.168

−0.046

Urban

−0.143

−0.063

−0.129

−0.057

0.007

0.003

−0.119

−0.052

−0.169

−0.074

Living with vulnerable population
(Ref: No)

−0.230

−0.083

−0.215

−0.078

−0.043

−0.015

0.033

0.012

0.003

0.001

Family/friends tested positive
COVID-19

−0.016

−0.007

−0.076

−0.033

−0.064

−0.028

−0.019

−0.008

0.002

0.001

Central

0.067

0.004

0.045

0.002

0.214

0.011

0.235

0.013

0.122

0.007

East

0.317

0.047

0.246

0.037

0.211

0.031

0.348

0.052

0.061

0.009

North

−0.137

−0.057

−0.169

−0.070

−0.020

−0.008

0.055

0.023

0.013

0.005

Northeast

−0.285

−0.045

−0.321

−0.051

−0.367

−0.058

−0.370

−0.058

−0.502

−0.079

South

0.780

0.116

0.559

0.083

0.542

0.081

0.663

0.099

0.623 *

0.093

Union Territories

−0.323

−0.106

−0.278

−0.091

−0.082

−0.027

−0.107

−0.035

−0.146

−0.048

Fully vaccinated with primary series
(Ref: No)

-

-

0.479 *

0.143

0.339

0.101

0.151

0.045

−0.025

−0.007

Region (Ref: West)
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Table 5. Cont.
Variables

Model 1

Model 2

Model 3

Model 4

Model 5

Vaccine Confidence

-

-

0.324 **

0.231

0.074

0.053

0.003

0.002

−0.048

−0.034

Total Vaccine Literacy

-

-

0.018

0.098

0.013

0.070

0.006

0.035

−0.002

−0.011

Participatory dialogue

-

-

-

-

0.145 **

0.474

0.104 **

0.339

0.094 **

0.307

Behavioral confidence

-

-

-

-

-

-

0.179 **

0.417

0.070 *

0.164

Changes in the physical environment

-

-

-

-

-

-

-

-

0.181 **

0.441

R2

0.093

-

0.189

-

0.341

-

0.471

-

0.561

-

F

1.289

-

2.497 **

-

5.310 **

-

8.736 **

-

11.978 **

-

∆ R2

0.093

-

0.095

-

0.153

-

0.130

-

0.089

-

1.289

-

9.659 **

-

56.989 **

-

60.247 **

-

49.657 **

-

∆F

* p-value < 0.05; ** p-value < 0.001; Adjusted R2 of initiation in the final model = 0.514.

4. Discussion
The main objective of this study was to measure the factors associated with booster
dose hesitancy in India, with an emphasis on vaccine literacy and vaccine confidence. The
study was conducted after the approval of COVID-19 vaccine booster shots on 10th January
2022, by the Ministry of Health, Government of India. The emergence of coronavirus
variants, concerns around waning immunity with primary vaccine series and evidence
from other countries suggesting the benefits of additional doses to boost immunity were the
primary drivers of initiating booster dose vaccination in India in January 2022 [29–32]. Over
fifty percent (50%) of the participants in this study reported their willingness to take the
booster dose against COVID-19, which is consistent with the findings of previous studies
being conducted in other parts of the world [20,33,34]. Consistent with previous studies,
our results indicate a strong association between socio-economic factors, demographic
factors and vaccine acceptability [8,10,13,20,33,34]. With regards to gender, females were
significantly more booster hesitant than males. The possible explanation may be attributed
to persistent false messaging on social media about the association of COVID-19 vaccines
with female infertility or birth defects [34–36].
Among other sociodemographic characteristics, participants with lower income, lower
educational attainment, and those living in the rural areas were more hesitant to take the
booster dose. Undoubtedly, rural–urban disparity has widened in COVID-19 vaccination
status. Previous studies suggested that rural area residents have less general vaccine
confidence and a few opportunities to gain access to health literacy regarding COVID-19
and vaccination [37,38]. Being culturally conservative and less educated, rural residents are
more likely than urban residents to accept misinformation and conspiracy theories [38–41].
Additionally, the healthcare access in rural areas may not be adequate to provide large
scale care to COVID-19 patients. This highlights the need to develop stronger healthcare
infrastructure and culturally appropriate community education programs for the rural
communities. This would need extensive collaboration between government and the
members of the community, who may serve as trusted messengers or “COVID-19 vaccine
ambassadors” [38,39]. To promote equitable access to vaccines, mobile vaccination units
can be employed to target areas with lesser vaccination uptake in rural areas.
Next, the vaccine non-hesitant participants in our sample had significantly higher
scores of functional, communicative, and critical literacies as opposed to hesitant participants. This finding is consistent with one study which was performed in Bangladesh, in
which individuals with higher vaccine literacy had the greater vaccine acceptability [40].
This can be explained by the premise that individuals with high vaccine literacy will be
able more efficient in distinguishing false from accurate information. The non-hesitant
participants also had high mean scores of vaccine confidence and perceived advantages of
booster doses. As self-reported by the non-hesitant participants, they perceived COVID-19
as a serious illness and also think that the booster dose of the COVID-19 vaccine is effective.
These participants also believe that by taking booster dose, they can protect people close to
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them. This points to the sense of “collective responsibility” towards society and previous
studies described it as a stronger predictor of vaccine initiation behavior [41].
Finally, all the MTM constructs of vaccine initiation behavior, i.e., participatory dialogue, behavioral confidence, and changes in physical environment were statistically
significant predictors. This finding was consistent with a previous study which used MTM
based assessment among college students, in which all the three MTM constructs were significant predictors of vaccine initiation behaviors [18]. These findings point to developing
evidence-based interventions to initiate participatory dialogue between the “vaccine ambassador” or facilitators and community, emphasizing the advantages of vaccination over
the disadvantages. To increase the behavioral confidence, “vaccine ambassadors “can use
their own success stories as testimonials to help increase the vaccine uptake among hesitant
individuals. Given a strong and positive correlation between behavioral confidence and
vaccine confidence, the strategies outlined above will help in increasing vaccine confidence
too. The construct of “change in the physical environment” can be intervened by increasing
booster dose accessibility for the hard-to-reach communities, particularly those living in
rural areas. In areas where the vaccine is freely accessible, reminder systems to ensure the
completion of immunization through m-health intervention will be beneficial.
Strengths and Limitations
To our best knowledge, this study is the first to investigate booster dose acceptability
among the Indian population based on a robust theoretical model. However, this study is
not without limitations. First, owing to the cross-sectional nature of the study, causal inferences were not made. Additionally, as the responses were digitally obtained, biases might
have arisen from the housing conditions of the participants, in other words, environmental
biases, were not controlled in this study. Next, the outcome might have been impacted by
the social desirability bias. Moreover, due to differences in the characteristics of the eligible
(e.g., ability to understand English and electronic access) and non-eligible participants,
a “selection bias” might have been introduced into the study. The extent to which these
factors would have influenced selection bias was difficult to quantify as we were unable
to conduct a paper-based survey with a rural population lacking electronic access. At the
time of data collection, India was hit hard by the third wave of the pandemic which limited
our ability to conduct in-person surveys to minimize the effect of selection bias.
Next, the sample used in the study was not representative in terms of some demographic variables (e.g., age, marital status etc.), which might have impacted our ability
to extrapolate the findings to the entire nation. Additionally, we expect to have “residual
confounding” in this study as some variables, such as political and religion affiliation, were
left unmeasured. Future studies can be planned to investigate the causal impact of the
predictors being studied in the current investigation.
5. Conclusions and Implications
The universal acceptance of the COVID-19 booster dose among the diverse eligible
populations across countries will facilitate the eradication of the pandemic in the near future.
However, in reality booster dose vaccine hesitancy is still prevalent in many parts of the
world due to various socio-economic and behavioral factors; governments across nations
find this to be a challenge for wider vaccine coverage especially among the developing and
poorer countries.
Despite the high acceptance levels among the sampled Indian population of booster
dose uptake in this study, there is also a sizeable proportion of people who are vaccine
hesitant. Being unvaccinated with the initial doses, having lower income levels, living in
rural areas, not living with vulnerable individuals and not having family/friends who had
tested positive were the strong predictors. This study provides new insights into the fact
that high vaccine literacy and high vaccine confidence among the non-hesitant groups are
strong predictors of booster dose vaccine acceptance levels.
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There are important policy implications emerging from this study, which mainly highlight the need to create targeted educational campaigns to promote vaccine and health
literacy among vaccine hesitant groups to dispel their myths and fears. This can be done
by providing accurate and factual information about COVID-19 booster vaccination uptake to promote trust and acceptance in the vaccine. Additionally, among other countries
with similar demographic profiles as India, it is critical to design effective communication strategies and active solutions to promote understanding about vaccine efficacy and
effectiveness. For instance, vaccination uptake behavior promotion interventions can be
developed, which will propagate information related to the effectiveness of the booster
dose through community leaders and media. This will help increase the vaccine confidence
among hesitant individuals, particularly in developing countries. Additionally, some studies have indicated that modest monetary incentives can be helpful in raising the vaccination
rates [41].
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